WHO ICTRP trial
ROLE OF VORTIOXETINE ON COGNITION AND INFLAMMATION IN SCHIZOPHRENIA: A…
CTRI/2023/05/052648 · Clinical Trials Registry India (CTRI) · Not Recruiting
Key facts
| Trial ID | CTRI/2023/05/052648 |
|---|---|
| Public title | ROLE OF VORTIOXETINE ON COGNITION AND INFLAMMATION IN SCHIZOPHRENIA: A RANDOMIZED PLACEBO-CONTROLLED TRIAL |
| Scientific title | ROLE OF VORTIOXETINE ON COGNITION AND INFLAMMATION IN SCHIZOPHRENIA: A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED TRIAL |
| Primary sponsor | Central Institute of Psychiatry |
| Registry | Clinical Trials Registry India (CTRI) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | India |
| Conditions | Health Condition 1: F20- Schizophrenia |
| Interventions | Intervention1: Adjunctive vortioxetine therapy: Tablet Vortioxetine 5 mg/day orally for 5 days, after which the dose will be increased to 10 mg/day. After 5 days, the dose will be increased to 20 mg/day as tolerated and this dose will be… |
| Registration date | May 15, 2023 |
| Target size | 40 |
| Secondary IDs | NIL |
| Registry page | ctri.nic.in |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: